No­var­tis bags FDA OK for Ry­dapt, adding a new chemo com­bo drug for AML

No­var­tis has picked up a new drug ap­proval, this time for Ry­dapt (mi­dostau­rin, PKC412) for new­ly di­ag­nosed cas­es of acute myeloid leukemia among pa­tients with a spe­cif­ic FLT3 ge­net­ic mu­ta­tion. The drug will be used in com­bi­na­tion with a chemother­a­py and there’s a di­ag­nos­tic avail­able to ID the right pa­tients for this drug.

The drug, des­ig­nat­ed as a break­through ther­a­py at the FDA, is a ki­nase in­hibitor that tack­les en­zymes as­so­ci­at­ed with the ad­vance of the blood can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.